Clinical trials: Glaucoma Patients
Glaucoma
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH).
- Trial name
- NCT00763061
- Testing
- Travoprost 0.004% Ophthalmic Solution (Travatan), Timolol 0.5% Ophthalmic Solution (Timoptic)
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Glaucoma
AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure
The purpose of this study was to assess the safety and efficacy of switching to Azarga from prior pharmacotherapy in patients with open-angle glaucoma.
- Trial name
- NCT01484951
- Testing
- Brinzolamide 1% and timolol 0.5% fixed combination eye drops
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma (POAG)
A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial
The purpose of this study is to evaluate the long-term safety of the CyPass Micro-Stent in subjects who completed Study Protocol TMI-09-01, COMPASS Trial.
- Trial name
- COMPASS-XT (NCT02700984)
- Testing
- CyPass Micro-Stent, Cataract Surgery
- Where
- 22 sites in United States
- Volunteers
- 282 people
- Sponsor
- Alcon Research
Intraocular Pressure
Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily.
- Trial name
- NCT00758342
- Testing
- Travoprost 0.004% + Brinzolamide 1.0%, Travoprost 0.004% + Tears Natural
- Volunteers
- 37 people
- Sponsor
- Alcon Research
Normal Tension Glaucoma
Systemic Glutathione Level in Normal Tension Glaucoma
The purpose of this study is to evaluate whether systemic glutathione level is decreased in patients with normal tension glaucoma.
- Trial name
- NCT00570362
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- The Catholic University of Korea
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01241240
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- 2 sites in Colombia, Mexico
- Volunteers
- 192 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study and will evaluate IOP reduction in newly diagnosed patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians…
- Trial name
- NCT01628614
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 4,812 people
- Sponsor
- Allergan
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01518244
- Testing
- Brinzolamide/timolol maleate fixed combination
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Keratoconus, Glaucoma
Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus
The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that increased Intraocular Pressure (IOP) is a major risk factor.
- Trial name
- NCT03560609
- Testing
- Ophthalmodynamometer, Goldmann applanation tonometer, Pentacam
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Glaucoma
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when Simbrinza is used adjunctively to Travatan in patients with normal tension glaucoma that may benefit from…
- Trial name
- NCT03150160
- Testing
- brinzolamide 1%/brimonidine 0.2% fixed combination, travoprost 0.004% ophthalmic solution
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma, Dry Eyes
Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
Research indicates that many people who are being treated for glaucoma have dry eyes. The purpose of this study is to test the use of artificial tears to alleviate dryness signs and symptoms in people who are using medication to…
- Trial name
- IVES (NCT01682460)
- Testing
- Refresh Tears Lubricant Eye Drops (Allergan)
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University of Waterloo
Glaucoma, Open-Angle, Ocular Hypertension
Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately…
- Trial name
- NCT02507687
- Testing
- Bimatoprost SR, Selective Laser Trabeculoplasty
- Where
- 95 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- AbbVie
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01632423
- Testing
- bimatoprost 0.01%
- Where
- Germany
- Volunteers
- 10,337 people
- Sponsor
- Allergan
Glaucoma and Ocular Hypertension
Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
This is a multiple cohort study that will evaluate the safety and efficacy of ENV515 travoprost XR in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02371746
- Testing
- ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
- Where
- 14 sites in United States
- Volunteers
- 41 people
- Sponsor
- Envisia Therapeutics
Glaucoma
Efficacy of Glaucoma Drop Aids in Medication Compliance in the Patient Population at Boston Medical Center
The purpose of this study is to determine whether glaucoma drop aids will be cost-effective in delivery of ophthalmic medications by improving medication compliance, visual function, and even decreasing medication waste in the…
- Trial name
- NCT02867995
- Testing
- Eye Drop Aid
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Boston Medical Center
Open-Angle Glaucoma, Ocular Hypertension
Efficacy of Changing to DUOTRAV® From Prior Therapy
The purpose of this study was to assess the efficacy and tolerability of changing to DUOTRAV® from prior bimatoprost 0.03%/timolol 0.5% pharmacotherapy in subjects with open-angle glaucoma or ocular hypertension having…
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT01327599
- Testing
- Travoprost 0.004%+Timolol 0.5% ophthalmic solution
- Volunteers
- 60 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular…
- Trial name
- NCT01735214
- Testing
- Prostaglandin Analogue -Containing IOP-Lowering Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 358 people
- Sponsor
- Allergan
Ocular Hypertension, Glaucoma
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or…
- Trial name
- NCT00809848
- Testing
- AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Allergan
Glaucoma
COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
A study to evaluate the effect of the 12-week treatment with timolol/dorzolamide combination eyedrops (COSOPT) on decrease in intraocular pressure (IOP) at 2 hours after the study drug administration
- Trial name
- NCT00832377
- Testing
- timolol/dorzolamide combination
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC